Supplemental Table S1 provides an overview of ongoing clinical trials. For example, MEDI0457 (also named INO-3112) [51], a DNA vaccine with a synthetic plasmid targeting E6 and E7 of HPV-16/18 and IL-12, was tested in combination with the PD-L1 targeting antibody durvalumab in a phase Ib/II clinical trial for patients with recurrent/metastatic HPV-associated HNSCC (NCT03162224). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.